Eighty-six drugs were newly reported as in short supply this year through July 31, down from 204 through the end of 2012, but the total number of active shortages held steady at 302, according to the University of Utah Drug Information Service. The FDA Safety and Innovation Act mandates that drugmakers notify the agency about possible shortages of key drugs, but it does not require drugmakers to address quality problems or manufacture more generic drugs, FDA spokesman Stephen King said.

Related Summaries